Endo Acquires Johnson Matthey's Oxymorphone Patent
CHADDS FORD, Pa., March 22, 2012 /PRNewswire/ -- Endo (Nasdaq: ENDP) announced today that it has acquired U.S. patent 7,851,482 B2 for oxymorphone hydrochloride, the key API in all formulations of OPANA, from Johnson Matthey plc. Johnson Matthey is a leading supplier of active pharmaceutical ingredients through its worldwide Fine Chemicals Division.
By acquiring Johnson Matthey's patent to the oxymorphone ingredient, which will be listed in the U.S. Food and Drug Administration's Orange Book, Endo will enjoy additional patent protection for its OPANA franchise, now through 2029.
"This patent not only covers our newly designed to be crush resistant OPANA® ER, it covers all products that include oxymorphone that are manufactured in accordance with current FDA specifications," said Julie McHugh, chief operating officer of Endo.
About Endo
Endo Pharmaceuticals Holdings Inc. (Endo) is a US-based diversified
healthcare company that is redefining healthcare value by finding
solutions for the unmet needs of patients along care pathways for
pain management, pelvic health, urology, endocrinology and
oncology. Through our operating companies: AMS, Endo
Pharmaceuticals, HealthTronics and Qualitest, Endo is dedicated to
improving care through a combination of branded products, generics,
devices, technology and services that creates maximum value for
patients, providers and payers alike. Learn more at
www.endo.com.
Safe Harbor Statement
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements including words such as "believes," "expects,"
"anticipates," "intends," "estimates," "plan," "will," "may," "look
forward," "intend," "guidance," "future" or similar expressions are
forward-looking statements. Because these statements reflect our
current views, expectations and beliefs concerning future events,
these forward-looking statements involve risks and uncertainties.
Investors should note that many factors, as more fully described
under the caption "Risk Factors" in our Form 10-K, Form 10-Q and
Form 8-K filings with the Securities and Exchange Commission and as
otherwise enumerated herein or therein, could affect our future
financial results and could cause our actual results to differ
materially from those expressed in forward-looking statements
contained in our Annual Report on Form 10-K. The forward-looking
statements in this press release are qualified by these risk
factors. These are factors that, individually or in the aggregate,
could cause our actual results to differ materially from expected
and historical results. We assume no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future developments or otherwise.
SOURCE Endo
CONTACT: Investors/Media, Blaine Davis, +1-610-459-7158, Media,
Kevin Wiggins, +1-610-459-7281, Investors, Jonathan Neely,
+1-610-459-6645
Web Site: http://www.endo.com
Posted: March 2012
